Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HH160 · 1 trial · 12 indications
Assessed by treatment-emergent adverse events (TEAEs), serious adverse events (SAEs). and adverse events meeting protocol-defined dose-limiting toxicity (DLT) criteria.
The MTD or MAD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 28%, or the highest dose administered, respectively.
| Arm | Type | Description |
|---|---|---|
| Phase 1a Part 1 : Dose Escalation | EXPERIMENTAL | Participants with advanced solid tumors will receive escalating doses of HH160 |
| Phase 1a Part 2: Safety Expansion | EXPERIMENTAL | Participants with selected advanced solid tumors, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), and other tumor types, will receive HH160 at dose levels determined to be tolerable during dose escalation to further evaluate safety and tolerability. |
| Name | Type | Description |
|---|---|---|
| HH160 | DRUG | Administered by intravenous infusion every 3 weeks (Q3W) |
Key Inclusion Criteria 1. Adults aged 18 to 75 years with signed informed consent. 2. Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements. 3. At least 1 measurable lesion per RECIST v1.1. 4. Eastern Cooperative Oncology Group Performance Statu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
HH160 is an investigational small molecule being studied for the treatment of advanced solid tumors, including non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, head and neck squamous cell carcinoma, renal cell carcinoma, endometrial cancer, cervical cancer, small-cell lung cancer, triple negative breast cancer, urothelial carcinoma, and gastroesophageal adenocarcinoma.
HH160 targets PD-1, VEGF-A, and CTLA-4, which are proteins involved in immune regulation and tumor growth. By targeting these proteins, HH160 is designed to modulate immune responses and inhibit tumor-associated pathways in solid tumors.
HH160 is being developed by BeOne Medicines Ltd., a biopharmaceutical company listed on the stock exchange under the ticker symbol ONC. The company is conducting clinical research to evaluate the safety and efficacy of HH160 in patients with advanced solid tumors.
HH160 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is currently being studied in a first-in-human trial to assess its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
HH160 is being evaluated in a Phase 1 clinical trial with the identifier NCT07623369, titled 'A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors.' This trial is not yet recruiting and plans to enroll approximately 56 participants aged 18 years and older.
HH160 is a distinct investigational small molecule that simultaneously targets PD-1, VEGF-A, and CTLA-4. While it shares molecular targets with some approved immunotherapies, HH160 is a unique compound developed by BeOne Medicines Ltd. and is not the same as any other drug.